key: cord-0967173-679ds029 authors: Mousavi, Seyed Abbas; Heydari, Keyvan; Mehravaran, Hossein; Saeedi, Majid; Alizadeh‐Navaei, Reza; Hedayatizadeh‐Omran, Akbar; Shamshirian, Amir title: Melatonin effects on sleep quality and outcomes of COVID‐19 patients: An open‐label, randomized, controlled trial date: 2021-09-08 journal: J Med Virol DOI: 10.1002/jmv.27312 sha: cfaffaa650f2f0b5030df98f00997aa2fc407b36 doc_id: 967173 cord_uid: 679ds029 This trial aims to evaluate the effectiveness of adding melatonin to the treatment protocol of hospitalized coronavirus disease 2019 (COVID‐19) patients. This was an open‐label, randomized controlled clinical trial in hospitalized COVID‐19 patients. Patients were randomized into a treatment arm receiving melatonin plus standard care or a control arm receiving standard care alone. The trial's primary endpoint was sleep quality examined by the Leeds Sleep Evaluation Questionnaire (LSEQ). The trial's secondary endpoints were symptoms alleviation by Day 7, intensive care unit admission, 10‐day mortality, white blood cell count, lymphocyte count, C‐reactive protein status, and peripheral capillary oxygen saturation. Ninety‐six patients were recruited and allocated to either the melatonin arm (n = 48) or control arm (n = 48). Baseline characteristics were similar across treatment arms. There was no significant difference in symptoms on Day 7. The mean of the LSEQ scores was significantly higher in the melatonin group (p < 0.001). There was no significant difference in laboratory data, except for blood oxygen saturation, which has improved significantly in the melatonin group compared with the control group (95.81% vs. 93.65% respectively, p = 0.003). This clinical trial study showed that the combination of oral melatonin tablets and standard treatment could substantially improve sleep quality and blood oxygen saturation in hospitalized COVID‐19 patients. The coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and resulting continue to cause a serious public health issue. Currently, there are millions of confirmed cases, including more than three million deaths. 1 The key symptoms of COVID-19 are cough, fever, and dyspnea from 2 to 14 days after infection. Infected patients can be asymptomatic carriers that can transmit the virus to the community without being affected and presenting symptoms or progress to mild, moderate, and severe stages. [2] [3] [4] Several therapeutic agents with different mechanisms have been used against COVID-19 and studied in clinical trials after months of effort. One of the principal trials, in this case, is the SOLIDARITY trial, 5, 6 which the World Health Organization (WHO) launched to study the effectiveness of interferon-beta, chloroquine/hydroxychloroquine, lopinavir-ritonavir, and remdesivir. The other large trial is the RECOVERY study, 7, 8 which includes several repurposed drugs (e.g., lopinavir-ritonavir, azithromycin, hydroxychloroquine, tocilizumab, REGN-COV2, and dexamethasone) and convalescent plasma administrated on hospitalized COVID-19 patients in the UK. Repurposing existing pharmaceuticals in such situations could be the best strategy to find an effective and safe agent. However, except the recommendation for steroid use in Severe and Critical stages of disease (https://www.covid19treatmentguidelines.nih.gov), there are no fully approved treatment approaches yet. Melatonin is the main neurohormone released by the pineal gland and a sleep-wake cycle regulator. 9 It is also a multifunctional hormone that affects most organ metabolism and plays a positive role in healthiness and aging. This chronobiotic agent could be effective against viral infections due to its antiapoptotic, immunomodulatory, anti-inflammatory, and antioxidative features. 10 Although an immunomodulatory effect has been hypothesized, the major known effect of melatonin is to recalibrate sleep-wake rhythms, 11 thereby possibly reducing the need for sedation in severely compromised hospitalized patients. 12 Previous studies have reported the promising performance of melatonin in improving acute respiratory stress caused by bacteria, radiation, virus, and so forth. [13] [14] [15] Different reviews have been published in recent months, suggesting the promising effects of melatonin against the COVID-19 pandemic. 10, [16] [17] [18] [19] Although there is inadequate experimental/clinical evidence regarding the effectiveness of melatonin against viral infections, especially SAS-CoV-2 infection, since there is an urgent need for an economical, viable, and widely available treatment for the current pandemic, it would be prudent to invest in a therapeutic agent that suggested by many scientists with reasonable evidence. In addition, sleep disorder is one of the main complaints among hospitalized COVID-19 patients, which develop during isolation treatment. 20 Thus, sleep disturbances in such individuals could be regulated with melatonin. Therefore, we conducted a randomized, active-controlled trial to evaluate the effectiveness of adding melatonin to hospitalized COVID-19 patients' routine treatment protocol. Hospitalized patients with COVID-19 typical symptoms such as fever, fatigue, cough, and so forth, as well as elevated C-reactive protein (CRP), were evaluated for inclusion if they were confirmed with chest computed tomography scan findings or reverse transcriptionpolymerase chain reaction nasopharyngeal swab for SARS-CoV-2 infection. Exclusion criteria were history of epilepsy, coagulation disorders, taking anticoagulants such as warfarin, and uncontrolled diabetes and blood pressure. All patients gave written informed consent for participation in the study. Patients were allocated to either the melatonin or control group alternately. Physicians, patients, and individuals who assessed the outcomes were not blinded for the assigned treatment. Categorical variables were analyzed using χ 2 and Fisher's exact test, and continuous variables were compared using the t-test and the Mann-Whitney U Test. The GLM univariate analysis was done for sex and age adjustments in treatment effect. A p value was considered statistically significant at the p < 0.05 threshold. Statistical analysis was performed using SPSS version 16.0. To conduct this trial, between April 14 and June 15, 2020, 105 patients were assessed for enrollment, of which 96 patients were eligible for entering the study. Out of 96 participants, 48 patients were randomized to the melatonin group and 48 patients to the control group ( Figure 1 ). The mean age of cases and controls was 51.06 (±15.86) and 54.77 (±15.34), respectively, and 55.2% of all patients were females ( Table 1) . The mean duration of symptoms onset to hospital admission was about eight days in both groups, and treatment duration (admission to discharge/death) was about 6 days (Table 1 ). The mean of the LSEQ score was significantly higher in the melatonin group for all four domains versus the control group ( Figure 2 ). Regarding symptom alleviation, there was no significant difference between the melatonin group and controls for all the considered symptoms on Day 7 ( Table 2 ). Six patients from the melatonin group (12.5%) and 10 patients from the control group (20.8%) were admitted to ICU; however, it was nonsignificant (p = 0.412) ( Table 1 ). As presented in Table 2 , laboratory data evaluation in Day 7 indicated no significant differences between the two groups regarding WBC count, lymphocyte count, and CRP levels. However, blood oxygen saturation has improved significantly in the melatonin group compared with the control group (95.81% vs. 93.65%, respectively, p = 0.003). On the 10th day of follow-up, one patient from the melatonin group (2.1%) and three patients from the control group (6.2%) died, but it was not significant (p = 0.617) ( Table 2) . In addition to the ongoing treatment approaches, multifunctional molecule melatonin has attracted scientists' attention for months, mainly due to its anti-inflammatory, antioxidative, and immunomodulatory functions. 35 In this case, previous studies demonstrate the successful performance of melatonin against sleep disorders, respiratory and atherosclerosis diseases, and viral infections (e.g., respiratory syncytial virus, Venezuelan equine encephalitis virus, hepatitis, and Ebola). [35] [36] [37] Although the role of melatonin in bat antiviral immunity is unclear, it seems that this agent has a potential role against SARS-CoV-2 through various pathways. 36, 38 Investigations showed that melatonin levels in different bats species range from 60 to 500 pg/ml and 20-90 pg/ml during night and day, respectively. 39, 40 However, melatonin concentration in humans is substantially lower, especially in older people. It has been reported that the melatonin night peak in the elderly is 11.2 (±1.6) pg/ml, which is significantly higher in young individuals (83 ± 20 pg/ml). Interestingly, the highest level of melatonin has been assessed in children between 1 and 3 years old with 329.5 (±42) pg/ml, 41, 42 those who seem to be much less likely to get COVID-19 in comparison with older ages. 43 This is one of the leading hypotheses toward less deterioration in adolescents than in elderly COVID-19 patients. Hence, given the available evidence and our findings, melatonin could be a useful supplement for both the healthy population and COVID-19 patients. Moreover, significant improvement of blood oxygen saturation in the melatonin group compared to the controls could be due to melatonin's influence on oxygen delivery and its utilization in tissues as one of the functions of melatonin, which studied experimentally and clinically. [54] [55] [56] [57] Decrease vascular permeability, therefore decreased pulmonary infiltration could be another explanation, albeit the present study did not evaluate pulmonary infiltration resolution during the hospitalization period between the two groups, which could be evaluated in further studies. Hence, it seems that it would be prudent to invest in more extensive clinical trials to find more about the melatonin associations with COVID-19 outcomes. In this case, a study on prophylactic effects of melatonin against COVID-19 is highly recommended by the authors. In the present study, the intervention group received daily 3 mg oral melatonin tablets. The best dose of melatonin for older adults has not been determined yet. 58 Albeit the reports regarding the ac- This study has several limitations as follows: (1) the study was open-label due to time restriction for placebo production in the current situation, (2) study was performed among hospitalized patients and hospital conditions may affect the sleep quality; and (3) the small sample size would lead to type II error. Future larger clinical trials are needed to robust the findings of this study with prolonged period and more detailed information. Coronavirus disease (COVID-19) SARS-CoV-2 viral load in upper respiratory specimens of infected patients Clinical characteristics of coronavirus disease 2019 in China Surviving sepsis campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19) Covid-19: what treatments are being investigated? Solidarity" clinical trial for COVID-19 treatments. World Health Organization (WHO) Situation reports Geneva: WHO A randomised trial of treatments to prevent death in patients hospitalised with COVID-19 (coronavirus) The RECOVERY platform Evidence for the efficacy of melatonin in the treatment of primary adult sleep disorders COVID-19: Melatonin as a potential adjuvant treatment Delirium and sleep disturbances in COVID-19: a possible role for melatonin in hospitalized patients Melatonin reduces the need for sedation in ICU patients: a randomized controlled trial Melatonin treatment improves adipose-derived mesenchymal stem cell therapy for acute lung ischemia-reperfusion injury Melatonin alleviates radiation-induced lung injury via regulation of miR-30e/NLRP3 Axis Inhibitory effect of melatonin on lung oxidative stress induced by respiratory syncytial virus infection in mice Can melatonin reduce the severity of COVID-19 pandemic? Therapeutic algorithm for use of melatonin in patients with COVID-19 Melatonin is a potential adjuvant to improve clinical outcomes in individuals with obesity and diabetes with coexistence of COVID-19 Clinical trial to test the efficacy of melatonin in COVID-19 Effects of progressive muscle relaxation on anxiety and sleep quality in patients with COVID-19 The Leeds Sleep Evaluation Questionnaire in psychopharmacological investigations: a review Cross-cultural validation of the Leeds Sleep Evaluation Questionnaire (LSEQ) in insomnia patients No benefit of hydroxychloroquine in COVID-19: results of systematic review and metaanalysis of randomized controlled trials Lopinavir-ritonavir in the treatment of COVID-19: a dynamic systematic benefit-risk assessment A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19 Clinical outcomes and plasma concentrations of baloxavir marboxil and favipiravir in COVID-19 patients: an exploratory randomized, controlled trial Favipiravir versus arbidol for COVID-19: a randomized clinical trial Experimental treatment with favipiravir for COVID-19: an open-label control study Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial Compassionate use of remdesivir for patients with severe COVID-19 Remdesivir and COVID-19 Remdesivir and its antiviral activity against COVID-19: A systematic review Emergency Use Authorization (EUA) information, and list of all current EUAs Dexamethasone in hospitalized patients with COVID-19: preliminary report Clinical trials for use of melatonin to fight against COVID-19 are urgently needed Melatonin potentials against viral infections including COVID-19: current evidence and new findings Melatonin: roles in influenza, COVID-19, and other viral infections Can melatonin reduce the severity of COVID-19 pandemic? V-H(+)-ATPase, Na(+)/K(+)-ATPase and NHE2 immunoreactivity in the gill epithelium of the Pacific hagfish (Epatretus stoutii) Melatonin rhythms and pineal structure in a tropical bat, Anoura geoffroyi, that does not use photoperiod to regulate seasonal reproduction Alterations in nocturnal serum melatonin levels in humans with growth and aging Age-dependent reduction in serum melatonin concentrations in healthy human subjects CDC COVID-19 Response Team. Coronavirus disease 2019 in children-United States Melatonin is significantly associated with survival of intubated COVID-19 patients. medRxiv Individualizing risk prediction for positive coronavirus disease 2019 testing: results from 11,672 patients Efficacy of melatonin with behavioural sleep-wake scheduling for delayed sleep-wake phase disorder: a double-blind, randomised clinical trial A randomized double-blind placebo-controlled trial of treatment as usual plus exogenous slow-release melatonin (6 mg) or placebo for sleep disturbance and depressed mood The effect of melatonin, magnesium, and zinc on primary insomnia in long-term care facility residents in Italy: a double-blind, placebo-controlled clinical trial Treating Insomnia during the COVID-19 pandemic: observations and perspectives from a behavioral sleep medicine clinic The challenge of mental health during COVID-19 outbreak: experience from metropolitan area of Milan The acute effects of the COVID-19 pandemic on insomnia and psychological symptoms Dealing with sleep problems during home confinement due to the COVID-19 outbreak: practical recommendations from a task force of the European CBT-I Academy Melatonin as adjuvant treatment for coronavirus disease 2019 pneumonia patients requiring hospitalization (MAC-19 PRO): a case series Effects of melatonin on the oxygen transport in blood, gas transmitters, and prooxidant-antioxidant balance in the exercise Participation of melatonin in regulation of blood oxygen-transport function in oxidative stress induced by injection of lipopolisaccharide Melatonin: an ancient molecule that makes oxygen metabolically tolerable Effect of melatonin on the blood oxygen transport during hypothermia and rewarming in rats Therapeutic algorithm for use of melatonin in patients with COVID-19 Estimated doses of melatonin for treating deadly virus infections: focus on COVID-19 Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus Disease (COVID-19)